Devices and methods are described for measuring formed blood component sedimentation rate. Some of the methods may use (1) centrifugal techniques for separating red blood cells from plasma and (2) video and/or still imaging capability. Both may be used alone or in combination to accelerate formed blood component sedimentation and to measure its rate. In one example, the method may advantageously enable rapid measurement of sedimentation rate using small blood sample volumes. Automated image analysis can be used to determine both sedimentation rate and hematocrit. Automated techniques may be used to compensate for effects of hematocrit on uncorrected sedimentation rate data.

The present invention relates to methods of detecting one or more targets of interest in a sample. In one instance, the target can be correlated to an active infection (e.g., by a virus and/or a bacterium). Methods can include treating the sample with a dissociation agent, thereby releasing the target of interest for more accurate detection (e.g., by use of a sedimentation-based centrifugal microfluidic devices). Also described herein are microfluidic devices and systems for use with a dissociation agent.

A method and device for analyzing a hematologic sample centrifuged within a capillary tube is provided. The device includes a tube holder, a sample imaging device, a processor, and a sample data display. The sample imaging device is operable to create a digital image of the sample within a region of the tube. The region is defined by substantially all of the radial width and axial length of the sample residing within the internal cavity of the tube in the region where the float resides after centrifugation. The sample imaging device is operable to produce signals representative of the image. The processor is adapted to produce information relating to bands of interest within the image based on the signals from the sample imaging device. The sample data display is adapted to display the results therefrom and/or a digital image of the sample within the region.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Provided is a method of making isolated exosomes containing an adeno-associated viral (AAV) vector, including disposing a suspension on an iodixanol gradient, wherein the suspension includes exosomes containing AAV vectors and the iodixanol gradient includes a higher layer of between 20% and 30% w/v iodixanol solution, an intermediate layer of between 30% and 50% w/v iodixanol solution, and a lower layer of between 50% and 70% w/v iodixanol solution, and centrifuging the iodixanol gradient at between 200,000 g and 300,000 g for at least 2 hours.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

A model-based method of classifying a specimen in a specimen container. The method includes capturing images of the specimen and container at multiple different exposures times, at multiple different spectra having different nominal wavelengths, and at different viewpoints by using multiple cameras. From the captured images, 2D data sets are generated. The 2D data sets are based upon selection of optimally-exposed pixels from the multiple different exposure images to generate optimally-exposed image data for each spectra. Based upon these 2D data sets, various components are classified using a multi-class classifier, such as serum or plasma portion, settled blood portion, gel separator (if present), tube, air, or label. From the classification data and 2D data sets, a 3D model can be generated. Specimen testing apparatus and quality check modules adapted to carry out the method are described, as are other aspects.

A liquid droplet forming device includes a liquid droplet discharger that discharges, as a liquid droplet, a particle suspension liquid in which one or more fluorescent particles are suspended; a light source for irradiating light onto the flying liquid droplet discharged from the liquid droplet discharger; a photodetector that receives fluorescence that is emitted by the one or more fluorescent particles included in the liquid droplet in response to the light as excitation light; and a particle number detector that detects a number of the one or more fluorescent particles included in the liquid droplet based on information from the photodetector.

Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.

A process for obtaining a monophasic liquid composition from a volume of a colloid; a monophasic liquid composition extracted from a colloid; a Kit for measuring the concentration of molecules solubilized in the continuous phase of a colloid, and a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.